Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nalbuphine ER for Cough in Idiopathic Pulmonary Fibrosis
NCT04030026Phase 2Completed
- Sponsor
- Trevi Therapeutics
- Start
- Oct 2019
- Primary completion
- May 2022
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of nalbuphine in idiopathic pulmonary fibrosis (IPF), sponsored by Trevi Therapeutics. Started Oct 2019; status: completed.
02
Drugs
nalbuphine
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on NCT04030026.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04030026.